

# CITATION REPORT

List of articles citing

## New Formulations of Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder: Pharmacokinetics, Efficacy, and Tolerability

DOI: 10.1007/s40263-017-0409-0  
CNS Drugs, 2017, 31, 149-160.

**Source:** <https://exaly.com/paper-pdf/66006386/citation-report.pdf>

**Version:** 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
20	Methylphenidate extended-release orally disintegrating tablets (Cotempla XR-ODT) in attention-deficit hyperactivity disorder in children aged 6-17 years: a profile of their use. <i>Drugs and Therapy Perspectives</i> , <b>2018</b> , 34, 43-49	1.5	
19	An update on the pharmacokinetic considerations in the treatment of ADHD with long-acting methylphenidate and amphetamine formulations. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2019</b> , 15, 937-974	5.5	11
18	Methylphenidate Alters Functional Connectivity of Default Mode Network in Drug-Naive Male Adults With ADHD. <i>Journal of Attention Disorders</i> , <b>2020</b> , 24, 447-455	3.7	5
17	The effectiveness of methylphenidate in improving cognition after brain injury in adults: a systematic review. <i>Brain Injury</i> , <b>2020</b> , 34, 1-10	2.1	4
16	A Pharmacokinetic Study of Methylphenidate Hydrochloride Multilayer Extended-Release Capsules (Aptensio XR) in Preschool-Aged Children with Attention-Deficit/Hyperactivity Disorder. <i>Paediatric Drugs</i> , <b>2020</b> , 22, 561-570	4.2	1
15	Drugs to Treat Attention Deficit Hyperactivity Disorder (ADHD). <b>2020</b> , 392-432		1
14	Individualization of attention-deficit/hyperactivity disorder treatment: pharmacotherapy considerations by age and co-occurring conditions. <i>CNS Spectrums</i> , <b>2021</b> , 26, 202-221	1.8	8
13	Encyclopedia of Molecular Pharmacology. <b>2021</b> , 1-8		
12	A clinician's guide for navigating the world of attention deficit hyperactivity disorder medications. <i>CNS Spectrums</i> , <b>2021</b> , 26, 104-114	1.8	0
11	Systematic review of transdermal treatment options in attention-deficit/hyperactivity disorder: implications for use in adult patients. <i>CNS Spectrums</i> , <b>2021</b> , 1-13	1.8	
10	A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Clinical Trial of ORADUR-Methylphenidate for Treating Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2021</b> , 31, 164-178	2.9	1
9	Methylphenidate for attention-deficit/hyperactivity disorder in adults: a narrative review. <i>Psychopharmacology</i> , <b>2021</b> , 238, 2667-2691	4.7	5
8	La doppia diagnosi ADHD e SUD. <i>Mission</i> , <b>2020</b> , 10-16	0	
7	Encyclopedia of Molecular Pharmacology. <b>2021</b> , 1321-1328		0
6	Effects of a single-dose methylphenidate challenge on resting-state functional connectivity in stimulant-treatment naive children and adults with ADHD.		
5	Children and Adolescents. 539-599		
4	Prediction of Carboxylesterase 1 (CES1)-mediated In Vivo Drug Interaction between Methylphenidate and Cannabinoids using Static and Physiologically Based Pharmacokinetic Models.. <i>Drug Metabolism and Disposition</i> , <b>2022</b> ,	4	0

- 3 Oral, intranasal, and intravenous abuse potential of serdexmethylphenidate, a novel prodrug of d-methylphenidate.. *Current Medical Research and Opinion*, **2022**, 1-40 2.5
- 2 Attention-Deficit/Hyperactivity Disorder in Prader-Willi Syndrome. **2022**, 68-76
- 1 Effects of a single-dose methylphenidate challenge on resting-state functional connectivity in stimulant-treatment naive children and adults with ADHD. *Human Brain Mapping*, 5.9 0